Quality of life of patients receiving a single or combination of calcium channel blocker-angiotensin receptor blocker: A cross-sectional study in West Java, Indonesia

Loading...
Thumbnail Image
Date
2020-03
Journal Title
Journal ISSN
Volume Title
Publisher
Open Science Publishers LLP
Abstract
The prevalence of hypertension, based on the Indonesian Basic Health Research 2018, was 34.1%. Hypertensivepatients usually show a low quality of life (QoL) due to their lifelong drug dependence. This cross-sectional study wasconducted to determine the QoL of adult hypertensive patients treated with a single calcium channel blocker (CCB)and combination of CCB and angiotensin receptor blocker (ARB) at a primary referral hospital in West Java duringDecember 2018–February 2019. The QoL of the patients was determined using the Indonesian validated Euroqol 5dimensions 5 level and Euroqol visual analog scale questionnaires. 83 adult hypertensive outpatients were recruitedand agreed to participate in this study. Of the 83 hypertensive patients, 44.6% were being treated with a single CCBand 55.4% were being given the combination of CCB and ARB. The characteristics of the patients were as follows:the age was 51 ± 1.04 years, 71.3% were female, 84.3% were married, 66.2% never undertook physical activity, dailydrugs consumed 4 ± 0.19 items, and the duration of hypertensive therapy was 20 ± 3.3 months. Most of the patientsindicated problems in the area of pain and anxiety. The hypertensive patients treated with a combination of nifedipineand candesartan indicated the best QoL, whereas the lowest QoL was found in patients treated with a combination ofnifedipine and valsartan.
Description
Keywords
Angiotensin receptor blocker, calcium channel blocker, hypertension, quality of life.
Citation
Ramadhani Juwita, Mutakin Mutakin, Perwitasari Dyah Aryani, Levita Jutti. Quality of life of patients receiving a single or combination of calcium channel blocker-angiotensin receptor blocker: A cross-sectional study in West Java, Indonesia. Journal of Applied Pharmaceutical Science. 2020 Mar; 2020 Mar: 088-092